Structure Therapeutics Inc. American Depositary Shares

HighVista Strategies sold 69,092 shares of Structure Therapeutics (worth $4.73 million) in Q1 2026, reducing its stake to 1.65% of AUM. Despite the fund's partial exit, Structure Therapeutics shares have surged 60% over the past year as the company advances its oral obesity drug candidate aleniglipron toward Phase 3 trials, with recent Phase 2 da...

Structure Therapeutics announced positive Phase 2 data for aleniglipron, an oral GLP-1 receptor agonist, showing placebo-adjusted weight loss of 16.3% at 180 mg and 16.0% at 240 mg at 44 weeks—the highest efficacy among oral GLP-1 receptor agonists with comparable results to injectable alternatives. The drug demonstrated improved tolerability w...

PatentVest released an analysis of 1,200+ patent documents across 50 oral small-molecule GLP-1 programs, revealing dramatic disparities in patent defensibility among competitors. With injectable GLP-1s reaching only 5% of eligible patients and clinical efficacy converging around 12-16% weight loss, long-term market dominance will depend on patent...

Structure Therapeutics CEO Ray Stevens outlined the company's strategy to compete in the crowded weight-loss drug market at the JPMorgan Healthcare Conference. The company plans to advance its daily oral GLP-1 candidate, aleniglipron, into Phase 3 trials. Phase 2 data showed 11% body weight loss at 36 weeks (adjusted for placebo), with higher dos...

FMR LLC, a Johnson family-controlled company and 10% owner of Structure Therapeutics, sold 52,356 shares worth approximately $3.8 million on December 8, 2025. Despite this insider sale, the clinical-stage biopharmaceutical company's stock has surged 212.55% over the past year, with continued momentum in 2026. The company recently closed a $748 mi...